PRISM BioLab Co.,LTD (206A.T)

JPY 232.0

(18.97%)

Market Cap (In JPY)

8.48 Billion

Revenue (In JPY)

112.92 Million

Net Income (In JPY)

-526.91 Million

Avg. Volume

153.81 Thousand

Currency
JPY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
285.0-672.0
PE
-6.92
EPS
-33.52
Beta Value
0.0
ISIN
JP3833190006
CUSIP
-
CIK
-
Shares
36579200.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
-
Employee Count
-
Website
http://www.prismbiolab.com
Ipo Date
2024-07-02
Details
PRISM Pharma Co., Ltd. operates as a pharmaceutical company that focuses on discovery and development of small molecules to modulate protein-protein interactions. It utilizes protein secondary structure mimetic library, which modulates intracellular protein and protein interactions. The firm develops an anti-cancer drug CP/Catenin inhibitor PRI-724 that acts on both cancer cells and cancer stem cells that can switch from proliferation to differentiation. The company was founded by Hiroyuki Kouji on November 2, 2006 and is headquartered in Fujisawa, Japan.